Presentation on Early Clinical Response to Sonata™ System Selected as Best Abstract In New Instrumentation/Technology Category Redwood City, CA—November 12, 2015 – Gynesonics, Inc., a women’s health technology company focused on the development and commercialization of breakthrough products
Gynesonics named to FierceMedicalDevices ‘2014 Fierce 15’
Designated ‘One of the Most Promising Private Med Tech Companies’ of 2014 REDWOOD CITY, CA – October 9, 2014 – Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced it has been named by
New CPT Code Established For Sonata™ System
AMA Establishes Code for Reimbursement of the Innovative Procedure for Uterine Fibroids Redwood City, CA – August 4, 2015 - Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that the American
Gynesonics Raises $43 Million in Equity Financing
Endeavour Vision and Abingworth Lead Funding Redwood City, CA - July 22, 2015 - Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that it has raised $43 million in an equity financing. The equity
Gynesonics’ Sonata™ System Winner of 2015 Medical Design Excellence Award
More than 100 Competitors in Medtech’s Premier Design Competition Redwood City, CA (June 30, 2015)—Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced that its Sonata System was selected as the
FAST-EU Trial 6 Month Results Published in Gynecological Surgery; 12 Month Results Presented at 43rd Annual AAGL Meeting
FAST-EU Trial 6 Month Results Published in Gynecological Surgery; 12 Month Results presented at 43rd Annual AAGL Meeting. REDWOOD CITY, CA – December 9, 2014 – Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine
FDA Grants Approval To Commence SONATA Pivotal IDE Clinical Trial
Distinct Alternative to Surgery, Radiological Approaches and Power Morcellation, for the Treatment of Symptomatic Uterine Fibroids. REDWOOD CITY, CA – October 22, 2014 – Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic
Gynesonics Names Richard P. Lanigan as Vice President, Global Commercialization
Veteran Medical Device Executive with Expertise in Clinical, Reimbursement, Sales, Marketing REDWOOD CITY, CA – August 7, 2014 – Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced it has